Congratulations to our brilliant scientist, Tobias Suske, on publishing his PhD study in the high-impact Journal of Clinical Investigation (JCI)!
In this paper, Tobias explored molecular mechanisms of how mutated hyperactive STAT5 causes T cell acute lymphoblastic leukemia (T-ALL). His work sheds light on the mechanisms underlying this disease and validates STAT5 as a key target in T-ALL and cancer.
We couldn’t be prouder to have him as part of our team, driving innovation and pushing scientific discovery’s boundaries.
We are delighted to announce that RIANAtx will be attending the LSX World Congress, from April 29th to April 30th in the vibrant city of London.
We look forward to presenting our recent data and connecting with early-stage investors in the life sciences and biotech community to foster new and exciting business opportunities!
We are delighted to announce that RIANAtx will be attending the BIO-EUROPE SPRING partnering conference, from March 18th to March 20th in the beauftiful city of Barcelona.
We look forward to presenting our recent data and connecting with leading business executives and early-stage investors in the life sciences and biotech community to foster new and exciting business opportunities!
In our endeavor to connect with leading business executives and early-stage investors in the life science and biotech community, it was a great pleasure to participate in the Inv€$tival Showcase and present our company in the “Startup Biotech” category.
We are delighted to announce that RIANAtx will be attending the BIO-EUROPE partnering conference, from November 6th to 8th in Munich, Germany.
We look forward to connecting with leading business executives and early-stage investors in the life sciences and biotech community to foster new and exciting business opportunities!
Vienna, Austria, and Dortmund, Germany, September 12 2023
RIANA Therapeutics, a spin-off from Vetmeduni Vienna founded in February 2023, announces that is has entered into a collaborative agreement with the Lead Discovery Center GmbH (LDC), a renowned organization specialized in translational drug discovery. This partnership marks the first important milestone on RIANA Therapeutics´ mission to discover and develop novel cancer therapeutics that disrupt oncogenic protein-protein interactions (PPIs).
Inhibition of PPIs is an emerging drug modality and a highly promising therapeutic approach for numerous diseases, including cancer, to overcome widespread resistance to drugs already in use and to improve treatment efficacy. Under the now-signed collaboration agreement, LDC will conduct a high-throughput screening (HTS) using a diverse compound library of more than 200,000 chemical substances to identify novel PPI inhibitors targeting STAT5, a critical mediator driving the development of Acute Myeloid Leukemia (AML).
Through the strategic partnership with LDC, RIANA Therapeutics secures invaluable access to LDC’s profound expertise in the field of early drug discovery. By combining their respective strengths, RIANA Therapeutics and LDC aim to accelerate the translation of innovative discoveries into potential therapeutics, with the declared long-term goal of improving the well-being of patients on a global scale.
Anna Orlova, co-founder and CEO of RIANA Therapeutics, expressed her excitement about the collaboration: “We are thrilled to partner with LDC, a highly experienced player in drug discovery. Their expertise and capabilities will be instrumental in our efforts to develop breakthrough therapeutics for hematopoietic and other cancer types. This collaboration marks a significant milestone for RIANA Therapeutics, and we look forward to working together to advance our shared mission of improving human health.”
Peter Nussbaumer, Managing Director at LDC, added: “We are highly motivated to start the challenging discovery of inhibitors targeting oncogenic PPI interactions within this new partnership with RIANA. This cooperation has the great potential to lay the groundwork for new, urgently needed therapeutic approaches for AML patients.”
From left to right: Oliver Szolar, Peter Nussbaumer, Anna Orlova, Christine Ruckenbauer, Richard Moriggl
About RIANA
RIANA Therapeutics was founded in February 2023 as a spin-off of Vetmeduni in Vienna founded by Anna Orlova, Richard Moriggl, and Oliver Szolar. The technological foundation is based on a proprietary platform technology for the discovery of compounds that target cancer-promoting protein-protein interactions (PPI), enabling a reliable search for inhibitors that block the formation of specific oncogenic PPIs. Building upon this novel proprietary technology, the team led by Orlova is working on developing new compounds specifically targeting AML, as well as other blood cancers and certain types of solid tumors.
Lead Discovery Center GmbH (LDC) was established in 2008 by the technology transfer organization Max Planck Innovation, as a novel approach to capitalize on the potential of excellent basic research for the discovery of new therapies for diseases with high medical need. The LDC takes on promising early-stage projects from academia and transforms them into innovative pharmaceutical leads and antibodies that reach initial proof-of-concept in animals as well as candidate nomination. In close collaboration with high-profile partners from research and industry, the LDC is building a strong and growing portfolio of small molecule and antibody leads with exceptional medical and commercial potential.
LDC sustains a long-term partnership with the Max Planck Society and its institutes as well as with KHAN-I, and has formed alliances with AstraZeneca, Bayer, Boehringer Ingelheim, Merck KGaA, Daiichi Sankyo, Qurient, InvIOS, Novo Nordisk, Cumulus Oncology, Nodus Oncology, JT Pharmaceuticals, KinSea AS, HLB Pharma, the Helmholtz Center for Infection Research, e.g. In addition, LDC also works with leading translational drug discovery centers and with various investors to provide its assets for company creation.
RIANA Therapeutics, ein Spin-off der Veterinärmedizinischen Universität Wien (Vetmeduni) entwickelt innovative Krebsmedikamente. Diese richten sich gezielt gegen krebsfördernde Protein-Protein-Wechselwirkungen.
In spring 2023, RIANA Therapeutics, a spin-off of Vetmeduni, kicked off its operations. With the aim of developing innovative cancer therapeutics, this biotech start-up leverages groundbreaking scientific insights from Vetmeduni’s Unit of Functional Cancer Genomics. A significant milestone has now been achieved with the signing of a license and cooperation agreement with the University of Veterinary Medicine Vienna.
Vice Rector Otto Doblhoff-Dier expressed his satisfaction with the successful transfer of Vetmeduni’s technologies into practical applications and praised the accomplishments of the RIANA Therapeutics team: “Every spin-off requires intensive scientific and organizational work, which the team has handled remarkably and with great professionalism.”
By finalizing the license agreement with Vetmeduni, Anna Orlova, co-founder, inventor, and CEO of RIANA, can celebrate a major success. The agreement grants the company exclusive worldwide rights to use the knowledge and findings on a platform technology for drug discovery that Orlova and her co-founder Richard Moriggl have developed at Vetmeduni over the past years. Additionally, RIANA gains access to office and laboratory facilities at the University Campus in Floridsdorf, Vienna, through a cooperation agreement with Vetmeduni. This allowed the young company to start its work without delay shortly after its establishment in April 2023.
Since May 2023, Anna Orlova, a passionate cancer researcher and entrepreneur, has been supported by Christine Ruckenbauer. With her nearly 20 years of expertise in technology transfer at Vetmeduni and her experience as the CEO of Vetmeduni’s research holding, where she successfully accompanied several spin-off companies since 2010, Ruckenbauer brings valuable contributions to the team. “After having mentored the RIANA team in my role at Vetmeduni for several years, I am thrilled to now have the opportunity to directly contribute to the company,” says Ruckenbauer.
Fotos: Thomas Suchanek/Vetmeduni
About RIANA Therapeutics
RIANA Therapeutics was founded in February 2023 as a spin-off of Vetmeduni in Vienna by Anna Orlova, Richard Moriggl, and Oliver Szolar, an experienced entrepreneur in the biotech industry. The technological foundation is based on a proprietary platform technology for the discovery of compounds that target cancer-promoting protein-protein interactions (PPI), enabling a reliable search for inhibitors that block the formation of specific oncogenic PPIs. Building upon this novel proprietary technology, the team led by Orlova is working on developing new compounds specifically targeting Acute Myeloid Leukemia (AML), as well as blood cancers and certain types of solid tumors in general.
We look forward to connecting with leading business executives and investors in the life sciences and biotech community to foster new and exciting business opportunities!
We are delighted to announce the incorporation of RIANA Therapeutics GmbH, a biotech startup focused on developing novel anti-cancer treatments. RIANA Therapeutics is a spinoff from Vetmeduni, devoted to discovering and developing innovative medicines. RIANA founders Richard Moriggl, Oliver Szolar, VetWidi, and Anna Orlova are very enthusiastic about committing to improving treatments for cancer patients. We are currently in the process of setting up research and development operations in Vienna and will keep you updated. See the full press release by Vetmeduni below:
RIANA Therapeutics 